Adverse Cutaneous Drug Reaction Following Granulocyte Colony-Stimulating Factor Administration in Nasopharynx Cancer Patient with Febrile Neutropenia: A Case Report

Introduction: Several side effects may occur during cancer treatment such as myelosuppression following systemic chemotherapy, which is mainly manifested neutropenia and associated with increased infection risk. Febrile a worse prognosis. Granulocyte colony-stimulating factor (G-CSF) be given prophylactically before chemotherapy in selected cases or adjuvant therapy febrile neutropenia. G-CSF administration several effects, including skin manifestation. More rarely, induce acute neutrophilic dermatosis known Sweet syndrome. Case Presentation: A 63-year-old man nasopharyngeal stage III on radiotherapy came to our emergency department chief complaint of fever, coughing, shortness breath. He was diagnosed community-acquired pneumonia His white blood cell (WBC) count 200/mm3 . On the third day hospitalization administration, he developed rash had desquamation his head scalp, face, lips, upper trunk, arms, surface both hands. follow-up laboratory result WBC 8300/mm3 neutrophil 87%. Presumable syndrome diagnosis differential other drug eruption reactions made. Systemic topical were administered, stopped. Significant improvement observed. Conclusions: neutropenic generally safe; however, adverse events occur. Cutaneous should recognized treated accordingly. rare but possible G-CSF-induced complication.